U.K. company is exploiting expertise via CRO, biomarker, and therapeutics divisions.
Japanese life science products distributor Veritas negotiated exclusive rights to market and distribute Epistem’s contract research services in Japan. U.K.-based Epistem is a specialist CRO offering research models, preclinical efficacy testing, and clinical sample analysis services that leverage its expertise in the field of adult epithelial stem cells and stem cell regulation.
The firm has a particular focus on the fields of oncology, mucositis, inflammatory bowel disease, wound healing, and skincare. Epistem already has a customer base in the U.S. and western Europe. It says the deal with Veritas will provide a sales and marketing presence in Japan to help further expand its research services within the Japanese market.
In addition to its CRO operations, Epistem operates separate biomarker and therapeutics divisions. The biomarker business is exploiting the firm’s GenetRx™ gene-expression platform and PathwayDirect™ database to identify and develop drug discovery, clinical, and therapeutic monitoring biomarkers in collaboration with industry partners.
The therapeutics division works in partnership with industry to identify new targets and develop protein therapeutic candidates that impact on the body’s natural regulators of stem cell regulators in areas including tissue regeneration, oncology, and gastrointestinal diseases.